May 21, 2019 / 12:30PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Good morning. Welcome to day 2 of the UBS Healthcare Conference. My name is Navin Jacob. I'm the senior analyst covering large-cap pharmaceuticals and SMID cap biotech.
I'm happy to have here with me today the management -- some of the management team from AbbVie. Today, we have Mike Severino, Vice Chairman and President as well as Robert Michael, SVP and CFO. Thanks for having us, guys.
Robert A. Michael - AbbVie Inc. - Senior VP & CFO
Pleasure to be here.
Questions and Answers:
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap PharmaceuticSo maybe we could start with a topic that is always in the front of investors' minds, HUMIRA ex U.S. and the erosion that we're seeing there. On the Q1 call, you guided to Q2 HUMIRA OUS revenues of $1 billion internationally. That's about 33%